Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Journal: Journal of viral hepatitis
Published: October 16, 2018
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Journal: Journal of medical virology
Published: October 12, 2018
Glecaprevir/Pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure.
Journal: Hepatology (Baltimore, Md.)
Published: September 14, 2017
Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment.
Journal: Hepatology (Baltimore, Md.)
Published: October 25, 2016
Real-World Effectiveness of Simeprevir-containing Regimens Among Patients With Chronic Hepatitis C Virus: The SONET Study.
Journal: Open forum infectious diseases
Published: August 19, 2016
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Journal: Journal of hepatology
Published: August 10, 2015
Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.
Journal: The Lancet. Infectious diseases
Published: June 21, 2012
Preliminary study of two antiviral agents for hepatitis C genotype 1.
Journal: The New England journal of medicine
Published: January 20, 2012
Showing 1-8 of 8
Last Updated: 09/26/2026